Alvotech enters the post-earnings tape with a Q1 revenue miss that landed after the close on May 6 — $105.9M against a $140.8M consensus — and a stock already under pressure heading in.
The miss is the story this week. The shares closed at $3.50 on Tuesday, down 0.57% on the day and 4.1% over the past month, so the market was not positioned for an upside surprise. After the print dropped, the company appeared in the "health care stocks moving in Wednesday's after-market session" round-ups — rarely a sign of a positive reaction. The revenue shortfall of roughly 25% against estimates will do the heavy lifting in framing how investors revisit the thesis heading into the May 7 call.
The earnings history adds texture. The last three prints before this week produced next-day moves of -1.0%, -7.1%, and -6.3% respectively, with the two most recent episodes extending further to -14.7% and -17.8% over the following five days. The pattern has been consistent: initial weakness on results day that compounds over the subsequent week. That context makes the post-print tape the primary thing to track in the days ahead.
Positioning in the lending market has eased noticeably from April peaks. Short interest came down from a recent high of 2.69% of the free float in late April to 2.14% by May 5 — a meaningful unwind over roughly two weeks. The borrow cost of 4.9% is unremarkable and has trended down from above 5.5% in mid-April. Availability has loosened compared to the tightest stretch of April, when the lending pool was more constrained. The ORTEX short score eased to 56.9 from 60.2 ten days ago — still in the moderate range, but the directional move shows bears pulling back ahead of the print rather than adding.
The Street picture is cautious. The most recent analyst actions came in mid-March: UBS cut its target from $10 to $6 while keeping a Buy, and Barclays lowered from $5 to $4 maintaining its Underweight call. The mean price target across covering analysts is around $13.83 — a figure that sits dramatically above the current $3.50 price. That gap almost certainly reflects stale targets from when the stock was trading materially higher, and should not be read as indicating near-term upside consensus of that magnitude. The stock carries a Hold consensus with bulls (UBS, Morgan Stanley at Overweight) facing a bear camp anchored by Barclays, which has been Underweight since initiating coverage in December 2025.
Factor scores highlight a genuine split in the data. EPS surprise ranks in the 99th percentile and 30-day EPS momentum scores 96 out of 100 — both suggest the company has been beating near-term estimates and seeing upward estimate revisions. But 90-day EPS momentum collapses to just 5, signalling that the longer-run earnings trajectory is weak. Short score ranks in the bottom quartile of the universe (26th percentile), and days-to-cover ranks at just 13 — consistent with the modest absolute short interest level.
One insider trade is worth noting. At the end of March, Aztiq Pharma Partners — the 33% controlling shareholder linked to founder and Chairman Robert Wessman — bought 318,000 shares at $3.29. That same day, Wessman himself sold an equivalent 318,000 shares at the same price in what appears to be an internal transfer rather than a directional market bet. Net insider activity over the past 90 days comes to a positive 636,000 shares and roughly $2.1M in value, but the internal nature of the transaction limits how much signal it carries for outside investors.
The ownership structure is concentrated. Aztiq controls 33.2% and Celtic Holdings holds a further 28.9%, meaning over 60% of shares outstanding sit with two related strategic holders. That structural overhang shapes liquidity and can limit the float available for new buyers, which matters more now that the stock is trading below $4.
What to watch next is straightforward: the market's reaction to management commentary on the May 7 earnings call, particularly any guidance updates on revenue ramp expectations for the remainder of 2026, will set the direction of travel for a stock that has now missed on revenue at three consecutive prints.
See the live data behind this article on ORTEX.
Open ALVO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
